FARON PHARMACEUTICALS OY
FARN | IL
Overview
Corporate Details
- ISIN(s):
- FI4000153309
- LEI:
- 7437009H31TO1DC0EB42
- Country:
- Finland
- Address:
- Joukahaisenkatu 6, FI-20520 TURKU
- Website:
- https://faron.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Faron Pharmaceuticals Oy is a global, clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments by leveraging the patient's immune system. The company focuses on addressing unmet medical needs in oncology through novel immunotherapies. Its lead asset, bexmarilimab, is a first-in-class, macrophage-targeting anti-Clever-1 antibody currently in Phase I/II clinical trials. Faron is investigating bexmarilimab's potential to improve the efficacy of standard-of-care treatments for patients with hematological malignancies and solid tumors, aiming to bring the benefits of immunotherapy to a broader patient population. The company's pipeline originates from academic discoveries, establishing it as a pioneer in myeloid cell-targeting therapies.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for FARON PHARMACEUTICALS OY.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-27 08:00 |
Earnings Release
FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025
|
English | 31.5 KB | |
| 2025-08-19 08:00 |
Report Publication Announcement
Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results
|
English | 5.1 KB | |
| 2025-08-18 08:00 |
Legal Proceedings Report
Inside Information: Faron to advance bexmarilimab into a registrational Phase 2…
|
English | 13.5 KB | |
| 2025-08-08 16:00 |
Major Shareholding Notification
Faron Pharmaceuticals Ltd: Holding(s) in Company
|
English | 47.7 KB | |
| 2025-08-08 09:30 |
Regulatory News Service
Faron announces extension to its key patent family around bexmarilimab and targ…
|
English | 9.7 KB | |
| 2025-08-07 08:00 |
Capital/Financing Update
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rig…
|
English | 10.1 KB | |
| 2025-08-06 08:00 |
Regulatory News Service
Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to…
|
English | 10.5 KB | |
| 2025-07-30 08:30 |
Regulatory News Service
FARON ANNOUNCES ACCEPTANCE OF BEXMARILIMAB DATA FOR ORAL PRESENTATION AT ESMO 2…
|
English | 13.3 KB | |
| 2025-07-09 08:00 |
Regulatory News Service
Faron announces acceptance of two studies involving bexmarilimab, one of them a…
|
English | 10.5 KB | |
| 2025-07-02 12:00 |
Director's Dealing
Faron Pharmaceuticals Ltd: Director Dealing
|
English | 25.2 KB | |
| 2025-06-30 13:00 |
Director's Dealing
Faron Pharmaceuticals Ltd: Director/PCA Dealing
|
English | 27.2 KB | |
| 2025-06-30 08:00 |
Regulatory News Service
Faron-supported research in Theranostics identifies secreted Clever-1 (sClever-…
|
English | 11.8 KB | |
| 2025-06-12 08:00 |
Earnings Release
Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2…
|
English | 13.2 KB | |
| 2025-06-05 17:00 |
Director's Dealing
Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Found…
|
English | 28.6 KB | |
| 2025-06-03 13:00 |
Share Issue/Capital Change
Faron Pharmaceuticals Ltd: Registration of New Shares
|
English | 8.3 KB |
Automate Your Workflow. Get a real-time feed of all FARON PHARMACEUTICALS OY filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for FARON PHARMACEUTICALS OY via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
